Neoplasms, Second Primary
"Neoplasms, Second Primary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Descriptor ID |
D016609
|
MeSH Number(s) |
C04.692
|
Concept/Terms |
Neoplasms, Second Primary- Neoplasms, Second Primary
- Neoplasm, Second Primary
- Second Primary Neoplasm
- Metachronous Second Primary Neoplasms
- Neoplasms, Metachronous
- Second Primary Neoplasms, Metachronous
- Second Malignancy
- Malignancies, Second
- Malignancy, Second
- Second Malignancies
- Second Neoplasm
- Neoplasm, Second
- Neoplasms, Second
- Second Neoplasms
- Second Primary Neoplasms
- Metachronous Neoplasms
- Metachronous Neoplasm
- Neoplasm, Metachronous
- Neoplasms, Metachronous Second Primary
Neoplasms, Therapy-Associated- Neoplasms, Therapy-Associated
- Neoplasm, Therapy-Associated
- Neoplasms, Therapy Associated
- Therapy-Associated Neoplasm
- Neoplasms, Treatment-Associated
- Neoplasm, Treatment-Associated
- Neoplasms, Treatment Associated
- Treatment-Associated Neoplasm
- Neoplasms, Treatment-Related
- Neoplasm, Treatment-Related
- Neoplasms, Treatment Related
- Treatment-Related Neoplasm
- Therapy-Related Neoplasms
- Therapy Related Neoplasms
- Treatment-Associated Neoplasms
- Treatment Associated Neoplasms
- Treatment-Related Neoplasms
- Treatment Related Neoplasms
- Neoplasms, Therapy-Related
- Neoplasm, Therapy-Related
- Neoplasms, Therapy Related
- Therapy-Related Neoplasm
- Therapy-Associated Neoplasms
- Therapy Associated Neoplasms
Therapy-Associated Cancer- Therapy-Associated Cancer
- Cancer, Therapy-Associated
- Cancers, Therapy-Associated
- Therapy Associated Cancer
- Therapy-Associated Cancers
- Therapy-Related Cancer
- Cancer, Therapy-Related
- Cancers, Therapy-Related
- Therapy Related Cancer
- Therapy-Related Cancers
- Treatment-Related Cancer
- Cancer, Treatment-Related
- Cancers, Treatment-Related
- Treatment Related Cancer
- Treatment-Related Cancers
- Treatment-Associated Cancer
- Cancer, Treatment-Associated
- Cancers, Treatment-Associated
- Treatment Associated Cancer
- Treatment-Associated Cancers
Cancer, Second Primary- Cancer, Second Primary
- Cancers, Second Primary
- Second Primary Cancer
- Second Primary Cancers
- Second Cancer
- Cancer, Second
- Cancers, Second
- Second Cancers
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms, Second Primary".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Second Primary".
This graph shows the total number of publications written about "Neoplasms, Second Primary" by people in this website by year, and whether "Neoplasms, Second Primary" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1992 | 3 | 0 | 3 | 1993 | 0 | 1 | 1 | 1994 | 1 | 0 | 1 | 1995 | 0 | 1 | 1 | 1996 | 5 | 0 | 5 | 1997 | 0 | 1 | 1 | 1998 | 3 | 0 | 3 | 1999 | 5 | 3 | 8 | 2000 | 5 | 5 | 10 | 2001 | 1 | 0 | 1 | 2002 | 3 | 0 | 3 | 2003 | 4 | 0 | 4 | 2004 | 5 | 2 | 7 | 2005 | 5 | 1 | 6 | 2006 | 4 | 5 | 9 | 2007 | 2 | 2 | 4 | 2008 | 4 | 1 | 5 | 2009 | 5 | 4 | 9 | 2010 | 5 | 2 | 7 | 2011 | 5 | 0 | 5 | 2012 | 6 | 3 | 9 | 2013 | 3 | 0 | 3 | 2014 | 6 | 2 | 8 | 2015 | 7 | 0 | 7 | 2016 | 8 | 1 | 9 | 2017 | 9 | 0 | 9 | 2018 | 2 | 0 | 2 | 2019 | 6 | 0 | 6 | 2020 | 5 | 0 | 5 | 2021 | 6 | 0 | 6 | 2022 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasms, Second Primary" by people in Profiles.
-
Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, Narayanan D, Ouseph MM, Kurzer JH, Hasserjian RP. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022 May 10; 6(9):2847-2853.
-
Li S, Zeng W, Ni X, Zhou Y, Stackpole ML, Noor ZS, Yuan Z, Neal A, Memarzadeh S, Garon EB, Dubinett SM, Li W, Zhou XJ. cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. Clin Cancer Res. 2022 May 02; 28(9):1841-1853.
-
Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, Lewis N, Chen X, Pelletier M, Chen X, Wu J, McWhirter SM, Müller T, Nair N, Luke JJ. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022 02 15; 28(4):677-688.
-
Mukand NH, Ko NY, Nabulsi NA, Hubbard CC, Chiu BC, Hoskins KF, Calip GS. The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women. Breast Cancer. 2022 Mar; 29(2):287-295.
-
Patel AA, Rojek AE, Drazer MW, Weiner H, Godley LA, Le Beau MM, Larson RA. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv. 2021 10 26; 5(20):4140-4148.
-
Henderson TO, Fowler BW, Hamann HA, Nathan PC, Whitton J, Leisenring WM, Oeffinger KC, Neglia JP, Turcotte LM, Arnold MA, Conces MR, Howell RM, Robison LL, Armstrong GT, Alexander KA. Subsequent malignant neoplasms in the Childhood Cancer Survivor Study: Occurrence of cancer types in which human papillomavirus is an established etiologic risk factor. Cancer. 2022 01 15; 128(2):373-382.
-
Turchan WT, Pitroda SP, Weichselbaum RR. Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res. 2021 10 01; 27(19):5188-5194.
-
Imgruet MK, Lutze J, An N, Hu B, Khan S, Kurkewich J, Martinez TC, Wolfgeher D, Gurbuxani SK, Kron SJ, McNerney ME. Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms. Blood. 2021 09 02; 138(9):790-805.
-
Daveri E, Luison E, Vallacchi V, Vergani B, Leone BE, Garassino MC, Figini M, Rivoltini L. Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes? Ann Oncol. 2021 06; 32(6):814-816.
-
Taylor J, Donoghue MT, Ho C, Petrova-Drus K, Al-Ahmadie HA, Funt SA, Zhang Y, Aypar U, Rao P, Chavan SS, Haddadin M, Tamari R, Giralt S, Tallman MS, Rampal RK, Baez P, Kappagantula R, Kosuri S, Dogan A, Tickoo SK, Reuter VE, Bosl GJ, Iacobuzio-Donahue CA, Solit DB, Taylor BS, Feldman DR, Abdel-Wahab O. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. J Clin Invest. 2020 12 01; 130(12):6668-6676.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|